Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease

Dementia and Geriatric Cognitive Disorders

Volumn 11, Issue SUPPL. 1, 2000, Pages 11-18

  Maelicke, Alfred ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Acetylcholine; Allosteric modulation; Alzheimer's disease; Galantamine; Nicotinic receptors

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; ACETYLCHOLINESTERASE; ANABASINE; ARECOLINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; GALANTAMINE; GLUTAMIC ACID; MUSCARINIC AGENT; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; OXOTREMORINE; SEROTONIN;

ALLOSTERISM; ALZHEIMER DISEASE; CHOLINERGIC SYSTEM; CHOLINERGIC TRANSMISSION; DRUG EFFICACY; DRUG TOLERABILITY; ENZYME INHIBITION; HUMAN; LEARNING; MEMORY; NEUROTRANSMISSION; PRIORITY JOURNAL; REVIEW; TRANSCRIPTION REGULATION;

EID: 0033813557     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000051227     Document Type: Review

References (66)

1. Ferris SH, Kluger A: Assessing cognition in Alzheimer's disease research. Alzheimer Dis Assoc Disord 1997;11:45-49.
2. Bartus RT, Dean RL 3rd, Beer B, Lippa AS: The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408-417.
3. Cummings JL, Back C: The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease. Am J Geriatr Psychiatry 1998;6(suppl 1):S64-S78.
4. Feldman H, Gracon S: Alzheimer's disease: Symptomatic drugs under development; in Gauthier S (ed): Clinical Diagnosis and Management of Alzheimer's Disease. London, Martin Dunitz Ltd, 1996.
5. Francis PT, Palmer AM, Snape M, Wilcock GK: The cholinergic hypothesis of Alzheimer's disease: A review of progress. J Neurol Neurosurg Psychiatry 1999;66:137-147.
6. Giacobini E: The cholinergic system in Alzheimer disease. Prog Brain Res 1990;84:321-332.
7. Schröder H, Giacobini E, Strubble RG, Zilles K, Maelicke A: Immunohistochemical and cytochemical localization of cortical nicotinic cholinoreceptors in rat and man. Brain Res Mol Brain Res 1991;502:287-295.
8. Schröder H, Wevers A: Nicotinic acetylcholine receptors in Alzheimer's disease. Alz Dis Rev 1998;3:20-27.
9. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR: Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science 1982;215:1237-1239.
10. Nordberg A, Alafuzoff I, Winbald B: Nicotinic and muscarinic subtypes in the human brain: Changes with aging and dementia. J Neurosci Res 1992;31:103-111.
11. Svensson AL, Alafuzoff I, Nordberg A: Characterization of muscarinic receptor subtypes in Alzheimer and control brain cortices by selective muscarinic antagonists. Brain Res 1992; 596:142-148.
12. Whitehouse PJ, Martino AM, Antuono PG, Lowenstein PR, Coyle JT, Price DL, Kellar KJ: Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Res 1986;371:146-151.
13. Nordberg A, Nilsson-Hakansson L, Adem A, Hardy J, Alafuzoff I, Lai Z, Herrera-Marschitz M, Winblad B: The role of nicotinic receptors in the pathophysiology of Alzheimer's disease. Prog Brain Res 1989;79:353-362.
14. Aubert I, Araujo DM, Cecyre D, Robitaille Y, Gauthier S, Quirion R: Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases. J Neurochem 1992;58:529-541.
15. Martin-Ruiz CM, Court JA, Molnar E, Lee M, Gotti C, Mamalaki A, Tsouloufis T, Tzartos S, Ballard C, Perry RH, Perry EK: α4 but not α3 and α7 nicotinic acetylcholine receptor sub-units are lost from the temporal cortex in Alzheimer's disease. J Neurochem 1999;73:1635-1640.
16. Haroutunian V, Kanof P, Davis KL: Pharmacological alleviation of cholinergic lesion induced memory deficits in rats. Life Sci 1985; 37:945-952.
17. Marks MJ, Stitzel JA, Collins AC: Influence of kinetics of nicotine administration on tolerance development and receptor levels. Pharmacol Biochem Behav 1987;27:505-512.
18. 3H]acetylcholine release from mouse cerebral cortical synaptosomes. J Neurochem 1984; 43:1593-1598.
19. Kerr JS, Sherwood N, Hindmarch I: Separate and combined effects of the social drugs on psychomotor performance. Psychopharmacology (Berl) 1991;104:113-119.
20. Wilson AL, Langley LK, Monley J, Bauer T, Rottunda S, McFalls E, Kovera C, McCarten JR: Nicotine patches in Alzheimer's disease: Pilot study on learning, memory, and safety. Pharmacol Biochem Behav 1995;51:509-514.
21. Newhouse PA, Sunderland T, Tariot PN, Blumhardt CL, Weingartner H, Mellow A, Murphy DL: Intravenous nicotine in Alzheimer's disease: A pilot study. Psychopharmacology 1988;95:171-175.
22. Newhouse PA, Potter A, Corwin J, Lenox R: Age-related effects of the nicotinic antagonist mecamylamine on cognition and behavior. Neuropsychopharmacology 1994;10:93-107.
23. Perry DC, Dávila-García MI, Stockmeier CA, Kellar KJ: Increased nicotinic receptors in brains from smokers: Membrane binding and autoradiography studies. J Pharmacol Exp Ther 1999;289:1545-1552.
24. Van Dujin CM, Hofman A: Relation between nicotine intake and Alzheimer's disease. BMJ 1991;302:1491-1494.
25. Marks MJ, Stitzel JA, Collins AC: Influence of kinetics on nicotine administration on tolerance development and receptor levels. Pharmacol Biochem Behav 1987;27:505-512.
26. Wonnacott S, Marks MJ: Nicotine: not just for cigarettes any more. Drug Discovery Today 1999;4:490-492.
27. Allen NH, Burns A: The treatment of Alzheimer's disease. J Psychopharmacol 1995;9:43-56.
28. Sarter M: Taking stock of cognition enhancers. Trends Pharmcol Sci Rev 1991;12:456-461.
29. Nordberg A, Svensson AL: Cholinesterase inhibitors in the treatment of Alzheimer's disease: A comparison of tolerability and pharmacology. Drug Saf 1998;19:465-480.
30. Potter A, Corwin J, Lang J, Piasecki M, Lenox R, Newhouse PA: Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease. Psychopharmacology (Berl) 1999;142:334-342.
31. Veroff AE, Bodick NC, Offen WW, Sramek JJ, Culter NR: Efficacy of xanomeline in Alzheimer disease: Cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB). Alzheimer Dis Assoc Disord 1998;12:304-312.
32. Weinstock M: The pharmacotherapy of Alzheimer's disease based on the cholinergic hypothesis: An update. Neurodegencration 1995; 4:349-356.
33. Flicker L: Acetylcholinesterase inhibitors for Alzheimer's disease. BMJ 1999;318:615-616.
34. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT and the Donepezil Study Group: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998;50:136-145.
35. Flint AJ, van Reekum R: The pharmacologic treatment of Alzheimer's disease: A guide for the general psychiatrist. Can J Psychiatry 1998; 43:689-697.
36. Allen H: Anti-dementia drugs. Int J Geriatr Psychiatry 1999;14:239-243.
37. Giacobini E: Cholinesterase inhibitors for Alzheimer's disease therapy: Pharmacokinetic and pharmacodynamic considerations; in Serge Gauthier (ed): Pharmacotherapy of Alzheimer's Disease. London, Martin Dunitz, 1998.
38. McKinney M, Coyle JT: The potential for muscarinic receptor subtype-specific pharmacotherapy for Alzheimer's disease. Mayo Clin Proc 1991;66:1225-1237.
39. Kihara T, Shimohama S, Sawada H, Kimura J, Kumc T, Kochiyama H, Maeda T, Akaike A: Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity. Ann Neurol 1997;42:159-163.
40. Marks MJ, Stitzel JA, Romm E, Wehner JM, Collins AC: Nicotinic binding sites in rat and mouse brain: Comparison of acetylcholine, nicotine, and alpha-bungarotoxin. Mol Pharmacol 1986;30:427-436.
41. Peng X, Gerzanich V, Anand R, Whiting PJ, Lindstrom J: Nicotine-induced increase in neuronal nicotinic receptors results from a decrease in the rate of receptor turnover. Mol Pharmacol 1994;46:523-530.
42. Court JA, Perry EK: CNS nicotinic receptors. Possible therapeutic targets in neurodegenerative disorders. CNS Drugs 1994;2:216-233.
43. Maelicke A, Albuquerque EX: New approach to drug therapy in Alzheimer's dementia. Drug Discovery Today 1996;1:53-59.
44. Kaczmarek L, Levitan I: Neuromodulation. New York, Oxford University Press, 1987.
45. Burnstock G: Mechanisms of interaction of peptide and nonpeptide vascular neurotransmitter systems. J Cardiovasc Pharmacol 1987; 10(suppl 12):S74-S81.
46. Rand MJ, Majewski H, Wong-Dusting H, Story DF, Loiacono RE, Ziogas J: Modulation of neuroeffector transmission. J Cardiovasc Pharmacol 1987;10(suppl 12):S33-S44.
47. Stahl SM: Essential Psychopharmacology. Cambridge University Press, 1996.
48. Haefely WE: Benzodiazepines. Int Anesthesiol Clin 1988;26:262-272.
49. Maelicke A, Schrattenholz A, Schröder H: Modulatory control by non-competitive agonists of nicotinic cholinergic neurotransmission in the central nervous system. Semin Neurosci 1995;7:103-114.
50. Albuquerque EX, Alkondon M, Pereira EF, Castro NG, Schrattenholz A, Barbosa CT, Bonfante-Cabarcas R, Aracava Y, Eisenberg HM, Maelicke A: Properties of neuronal nicotinic acetylcholine receptors: Pharmacological characterization and modulation of synaptic function. J Pharmacol Exp Ther 1997;280:1117-1136.
51. Thal LJ, Ferguson JM, Mintzer J, Raskin A, Targum SD: A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease. Neurology 1999;52: 1146-1152.
52. Alkondon M. Pereira EF, Eisenberg HM, Albuquerque EX: Choline and selective antagonists identify two subtypes of nicotinic acetylcholine receptors that modulate GABA release from CA1 interneurons in rat hippocampal slices. J Neurosci 1999;19:2693-2705.
53. Lawrence AD, Shahakian BJ: The cognitive psychopharmacology of Alzheimer's disease: Focus on cholinergic symptoms. Neurochem Res 1998;23:787-794.
54. Levin ED, Simon BB: Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology 1998;138:217-230.
55. Kihara T, Shimohama S, Urushitani M, Sawada H, Kimura J, Kume T, Maeda T, Akaike A: Stimulation of alpha4beta2 nicotinic acetylcholine receptors inhibits beta-amyloid toxicity. Brain Res 1998;792:331-334.
56. Schrattenholz A, Pereira EF, Roth U, Weber KH, Albuquerque EX, Maelicke A: Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Mol Pharmacol 1996;49:1-6.
57. Lilienfeld S, Parys W: Galantamine: Additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2000;11(suppl 1):19-27.
58. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Parys W, Ding C and the Galantamine USA-10 Study Group: A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000;54:2269-2276.
59. Bores GM, Huger FP, Petko W, Mutlib AE, Camacho F, Rush DK, Selk DE, Wolf V, KosIcy RW Jr, Davis L, Vargas HM: Pharmacological evaluation of novel Alzheimer's disease therapeutics: Acetylcholinesterase inhibitors related to galanthamine. J Pharmacol Exp Ther 1996;277:728-738.
60. Storch A, Schrattenholz A, Cooper JC, Abdel Ghani EM, Gutbrod O, Weber KH, Reinhardt S, Lobron C, Hermsen B, Soskic V, et al: Physostigminc, galanthamine and codeine act as 'noncompetetive nicotinic receptor agonists' on clonal rat pheochromocytoma cells. Eur J Pharmacol 1995;290:207-219.
61. Raskind M, Peskind E, Wessel T, Parys W, Yuan W and the Galantamine USA-1 Study Group: Galantamine in AD - a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000;54:2261-2268.
62. Imbimbo BP, Verdelli G, Martelli P, Marchesini D, and the Eptastigmine Study Group: Two-year treatment of Alzheimer's disease with eptastigmine. Dement Geriatr Cogn Disord 1999;10:139-147.
63. Rogers SL, Friedhoff LT: Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: An interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 1998; 8:67-75.
64. Newhouse PA, Potter A, Levin E: Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Drugs Aging 1997;11:206-228.
65. Court JA, Lloyd S, Thomas N, Piggott MA, Marshall EF, Morris CM, Lamb H, Perry RH, Johnson M, Perry EK: Dopamine and nicotinic receptor binding and the levels of dopamine and homovanillic acid in human brain related to tobacco use. Neuroscience 1998;87:63-78.
66. McGehee DS, Heath MJ, Gelber S, Devay P, Role LW: Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science 1995;269:1692-1696.